Industry News

 

Clinical courses

 

Clinical research courses

  • EMA recommends marketing authorisation for Truqap
    1 May 2024

    EMA recommends marketing authorisation for Truqap

    The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Truqap, intended for the treatment of locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations.
  • 1 May 2024
    Lilly Q1 2024 increased by 26 percent driven by Mounjaro, Zepbound, Verzenio and Jardiance

    In Q1 2024, worldwide revenue was USD 8.77 billion, an increase of 26 percent compared with Q1 2023, driven by increases of 16 percent in volume and 10 percent due to higher realized prices. The volume increase was primarily driven by growth from Mounjaro, Zepbound, Verzenio and Jardiance, partially offset by declines in Trulicity.

  • 1 May 2024
    Sanofi has launched GLP-1 drug in India
    Soliqua is indicated as treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.
  • 30 April 2024
    ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals

    ONO Pharmaceutical, Co., Ltd and Deciphera Pharmaceuticals, Inc. announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for USD 25.60 per share in cash through a tender offer followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with Deciphera surviving as a wholly owned subsidiary of ONO.

  • 30 April 2024
    Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
    Sandoz received FDA approval for the first and only denosumab biosimilars, Jubbonti and Wyost, on March 5, 2024. Jubbonti and Wyost are interchangeable with and approved by FDA for all indications of reference medicines Prolia and Xgeva. They have the same dosage form, route of administration, dosing regimen and presentation as the respective reference medicines.
  • 27 April 2024
    USFDA approves Pfizer’s BEQVEZ
    BEQVEZ is a one-time treatment that is designed to enable people living with hemophilia B to produce FIX themselves rather than the current standard of care, which requires regular intravenous infusions of FIX that are often administered multiple times a week or multiple times a month.
  • 27 April 2024
    In-Cosmetics Global Exhibition & Conference 2024 held in Paris
    In-cosmetics Global 2024 is an international exhibition for the cosmetic industry. It is the meeting place for innovation and development in the entire cosmetics sector worldwide. In recent years, the cosmetics industry has significantly shifted towards using active and natural ingredients in beauty products. This trend reflects a growing consumer preference for skincare and makeup formulations that enhance appearance and offer tangible benefits for skin health.
  • 24 April 2024
    Novartis radioligand therapy Lutathera FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
    Lutathera is now the very first therapy approved specifically for children with GEP-NETs, offering new hope to young patients living with this rare cancer.
  • 24 April 2024
    Dr. Reddy’s issues voluntary recall of Sapropterin Dihydrochloride Powder
    Dr. Reddys Lab announced that it is voluntarily recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level due to powder discoloration in some packets leading to decreased potency. The issue was discovered during an accelerated stability test in addition to customer complaints.
  • 22 April 2024
    Zydus launches Mirabegron Extended-Release Tablets in the US
    Zydus Lifesciences launches Mirabegron Extended-Release Tablets, 25 mg in the US market. The company had earlier received final approval from the United States Food and Drug Administration USFDA to market Mirabegron Extended-Release Tablets USP 25 mg and 50 mg. Mirabegron is indicated for the treatment of overactive bladder OAB with symptoms of urge urinary incontinence, urgency and urinary frequency
Subscribe to Industry News

Subscribe with us




 


 

 

Do Not Forget to Verify

(Click on Subscription link in your inbox)

--------

whatsapp

 

Also Join:  youtube  telegram

admission for pharma MBA

 

admission for pharma MBA

Jobs by Category

Production Jobs

R&D Jobs

F&D Jobs

Sales & Marketing

QA Jobs

QC Jobs

Faculty Jobs

CRO Jobs

DRA Jobs

IPR Jobs

IT Jobs

Packaging Alerts

Hospital Pharmacist